Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals

Bo Sun; Maie S. Taha; Benjamin Ramsey; Sandra Torregrosa-Allen; Bennett D. Elzey; Yoon Yeo

doi:10.1016/j.jconrel.2016.05.056

Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals

Bo Sun
, Maie S. Taha
, Benjamin Ramsey
, Sandra Torregrosa-Allen
, Bennett D. Elzey
, Yoon Yeo

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system.

Original language	English (US)
Pages (from-to)	91-98
Number of pages	8
Journal	Journal of Controlled Release
Volume	235
DOIs	https://doi.org/10.1016/j.jconrel.2016.05.056
State	Published - Aug 10 2016
Externally published	Yes

Keywords

Drug delivery
Hydrogel depot
Intraperitoneal chemotherapy
Nanocrystals
Ovarian cancer

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.jconrel.2016.05.056

Cite this

@article{8c8f736d40f649d9896ae1a6575dd423,

title = "Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals",

abstract = "Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system.",

keywords = "Drug delivery, Hydrogel depot, Intraperitoneal chemotherapy, Nanocrystals, Ovarian cancer",

author = "Bo Sun and Taha, \{Maie S.\} and Benjamin Ramsey and Sandra Torregrosa-Allen and Elzey, \{Bennett D.\} and Yoon Yeo",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2016",

month = aug,

day = "10",

doi = "10.1016/j.jconrel.2016.05.056",

language = "English (US)",

volume = "235",

pages = "91--98",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals

AU - Sun, Bo

AU - Taha, Maie S.

AU - Ramsey, Benjamin

AU - Torregrosa-Allen, Sandra

AU - Elzey, Bennett D.

AU - Yeo, Yoon

PY - 2016/8/10

Y1 - 2016/8/10

N2 - Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system.

AB - Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system.

KW - Drug delivery

KW - Hydrogel depot

KW - Intraperitoneal chemotherapy

KW - Nanocrystals

KW - Ovarian cancer

UR - https://www.scopus.com/pages/publications/84973131339

UR - https://www.scopus.com/pages/publications/84973131339#tab=citedBy

U2 - 10.1016/j.jconrel.2016.05.056

DO - 10.1016/j.jconrel.2016.05.056

M3 - Article

C2 - 27238443

AN - SCOPUS:84973131339

SN - 0168-3659

VL - 235

SP - 91

EP - 98

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this